Details van artikel 232 van 2578 gevonden artikelen
A pilot phase IV open label study investigating the safety and tolerability of switching from the Exelon patch 9.5mg daily to Aricept 23mg daily in patients with moderate to severe AD
Titel:
A pilot phase IV open label study investigating the safety and tolerability of switching from the Exelon patch 9.5mg daily to Aricept 23mg daily in patients with moderate to severe AD